Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease. 

Latest Publications

  • CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization
    Werr L, Plenker D, Dammert M A., Lorenz C, Brägelmann J, Tumbrink H L., Klein S, Schmitt A, Büttner R, Persigehl T, Shokat K M., Wunderlich T, Schram A M., Peifer M, Sos M L, Reinhardt H C., Thomas R K.
    Mol Cancer Ther. 2022 Feb
  • Chromothripsis followed by circular recombination drives oncogene amplification in human cancer
    Rosswog C, Bartenhagen C, Welte A, Kahlert Y, Hemstedt N, Lorenz W, Cartolano M, Ackermann S, Perner S, Vogel W, Altmüller J, Nürnberg P, Hertwig F, Göhring G, Lilienweiss E, Stütz AM, Korbel JO, Thomas RK, Peifer M, Fischer M.
    Nat Genet. 2021 Dec;53(12):1673-1685. doi: 10.1038/s41588-021-00951-7. Epub 2021 Nov 15.
    PMID: 34782764
  • Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
    Hudecova I, Smith CG, Hänsel-Hertsch R, Chilamakuri C, Morris JA, Vijayaraghavan A, Heider K, Chandrananda D, Cooper WN, Gale D, Garcia-Corbacho J, Pacey SC, Baird R, Rosenfeld N, Mouliere F. 
    Genome Res. 2021 Dec 20